Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.50 |
| ▸ | HNF4A | P41235 | 2/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | DCLRE1A | Q6PJP8 | 1/20 | 0.45 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 2/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24355022 | 0.86 | DCLRE1B (0.51) | ALDH1A1ALOX15DCLRE1BDHODH | |
| SCHEMBL17491075 | 0.85 | KDM4E (0.47) | ALDH1A1ALOX15AKR1C2AKR1C1RARB | |
| SCHEMBL121429 | 0.85 | ACMSD (0.63) | ACMSDHNF4AAKR1C2AKR1C1DHFR | |
| SCHEMBL31725051 | 0.85 | ACMSD (0.63) | ACMSDHNF4AAKR1C2AKR1C1DHFR | |
| SCHEMBL21199826 | 0.85 | ALDH1A1 (0.50) | ALDH1A1ALOX15AKR1C2RARBRARA | |
| SCHEMBL11037121 | 0.82 | ACMSD (0.55) | ACMSDHNF4AAKR1C2AKR1C1DHFR | |
| SCHEMBL205752 | 0.82 | ROCK2 (0.48) | ALDH1A1ALOX15RARBRARARARG | |
| SCHEMBL30837210 | 0.81 | MAPT (0.52) | ACMSDHNF4AAKR1C2AKR1C1DHFR | |
| SCHEMBL13927718 | 0.81 | IKBKB (0.61) | ACMSDHNF4AAKR1C2AKR1C1DHFR | |
| SCHEMBL30131431 | 0.81 | IKBKB (0.61) | ACMSDHNF4AAKR1C2AKR1C1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436249-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| WO-2007107005-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE, INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107005-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE, INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1436249-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003027061-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | CHRM1, CHRM2, CHRM4 | ALDH1A1 251/4885ALOX15 1405/4885ACMSD 1945/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | ALDH1A1 3139/4885ALOX15 4095/4885ACMSD 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.